Profile
Ana Radeljevic is Chief Executive Officer at Adventus Partners since 2016.
Ms. Radeljevic is Chief Business Officer at ADRx, Inc. since 2021.
Ms. Radeljevic was Independent Director at Merrimack Pharmaceuticals, Inc. from 2022 to 2025.
Ms. Radeljevic was Vice President-Financial Planning & Analysis at Revvity, Inc. from 2014 to 2016.
Ms. Radeljevic earned an MBA from Syracuse University and an undergraduate degree from Old Dominion University.
Ana Radeljevic active positions
| Companies | Position | Start |
|---|---|---|
ADRx, Inc.
ADRx, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology drug discovery company focused on developing small-molecule therapies for neurodegenerative diseases | Corporate Officer/Principal | 2021-08-31 |
Former positions of Ana Radeljevic
| Companies | Position | End |
|---|---|---|
| MERRIMACK PHARMACEUTICALS | Director/Board Member | 2025-05-19 |
| REVVITY, INC. | Corporate Officer/Principal | 2015-12-31 |
Training of Ana Radeljevic
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Revvity, Inc.
Revvity, Inc. Medical SpecialtiesHealth Technology Manufactures and distributes reagents, analytical instruments and develops software | Health Technology |
Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes drugs for the treatment of immunological & autoimmune diseases and cancer | Health Technology |
Syracuse University
Syracuse University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Old Dominion University
Old Dominion University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ADRx, Inc.
ADRx, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology drug discovery company focused on developing small-molecule therapies for neurodegenerative diseases | Commercial Services |
- Stock Market
- Insiders
- Ana Radeljevic
















